SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, Antonia Ho, Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, Antonia Ho

Abstract

Background: Viral load kinetics and duration of viral shedding are important determinants for disease transmission. We aimed to characterise viral load dynamics, duration of viral RNA shedding, and viable virus shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in various body fluids, and to compare SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) viral dynamics.

Methods: In this systematic review and meta-analysis, we searched databases, including MEDLINE, Embase, Europe PubMed Central, medRxiv, and bioRxiv, and the grey literature, for research articles published between Jan 1, 2003, and June 6, 2020. We included case series (with five or more participants), cohort studies, and randomised controlled trials that reported SARS-CoV-2, SARS-CoV, or MERS-CoV infection, and reported viral load kinetics, duration of viral shedding, or viable virus. Two authors independently extracted data from published studies, or contacted authors to request data, and assessed study quality and risk of bias using the Joanna Briggs Institute Critical Appraisal Checklist tools. We calculated the mean duration of viral shedding and 95% CIs for every study included and applied the random-effects model to estimate a pooled effect size. We used a weighted meta-regression with an unrestricted maximum likelihood model to assess the effect of potential moderators on the pooled effect size. This study is registered with PROSPERO, CRD42020181914.

Findings: 79 studies (5340 individuals) on SARS-CoV-2, eight studies (1858 individuals) on SARS-CoV, and 11 studies (799 individuals) on MERS-CoV were included. Mean duration of SARS-CoV-2 RNA shedding was 17·0 days (95% CI 15·5-18·6; 43 studies, 3229 individuals) in upper respiratory tract, 14·6 days (9·3-20·0; seven studies, 260 individuals) in lower respiratory tract, 17·2 days (14·4-20·1; 13 studies, 586 individuals) in stool, and 16·6 days (3·6-29·7; two studies, 108 individuals) in serum samples. Maximum shedding duration was 83 days in the upper respiratory tract, 59 days in the lower respiratory tract, 126 days in stools, and 60 days in serum. Pooled mean SARS-CoV-2 shedding duration was positively associated with age (slope 0·304 [95% CI 0·115-0·493]; p=0·0016). No study detected live virus beyond day 9 of illness, despite persistently high viral loads, which were inferred from cycle threshold values. SARS-CoV-2 viral load in the upper respiratory tract appeared to peak in the first week of illness, whereas that of SARS-CoV peaked at days 10-14 and that of MERS-CoV peaked at days 7-10.

Interpretation: Although SARS-CoV-2 RNA shedding in respiratory and stool samples can be prolonged, duration of viable virus is relatively short-lived. SARS-CoV-2 titres in the upper respiratory tract peak in the first week of illness. Early case finding and isolation, and public education on the spectrum of illness and period of infectiousness are key to the effective containment of SARS-CoV-2.

Funding: None.

© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Figures

Figure 1
Figure 1
Study selection MERS-CoV=Middle East respiratory syndrome coronavirus. SARS-CoV=severe acute respiratory syndrome coronavirus. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
Figure 2
Figure 2
Pooled mean duration (days) of SARS-CoV-2 shedding from the upper respiratory tract (random-effects model) SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
Figure 3
Figure 3
Pooled mean duration (days) of MERS-CoV shedding from the upper respiratory tract (random-effects model) MERS-CoV=Middle East respiratory syndrome coronavirus.
Figure 4
Figure 4
Pooled mean duration (days) of MERS-CoV shedding from the lower respiratory tract (random-effects model) MERS-CoV=Middle East respiratory syndrome coronavirus.

References

    1. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect. 2020;26:842–847.
    1. Zou L, Ruan F, Huang M. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–1179.
    1. Wölfel R, Corman VM, Guggemos W. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469.
    1. Kim ES, Chin BS, Kang CK. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020;35:e142.
    1. The Joanna Briggs Institute The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews. Checklist for case series. 2017.
    1. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
    1. Cai J, Xu J, Lin D. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020;71:1547–1551.
    1. Han MS, Seong M-W, Kim N. Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. Emerg Infect Dis. 2020;26:2497–2499.
    1. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-competent SARS-CoV-2 in nasopharynx of symptomatic neonates, children, and adolescents. Emerg Infect Dis. 2020;26:2494–2497.
    1. Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. J Clin Virol. 2020;127
    1. Wu Q, Xing Y, Shi L. Epidemiological and clinical characteristics of children with coronavirus disease 2019. medRxiv. 2020 doi: 10.1101/2020.03.19.20027078. published online March 26. (preprint)
    1. Xu Y, Li X, Zhu B. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26:502–505.
    1. Zhang Z, Xiao T, Wang Y. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. medRxiv. 2020 doi: 10.1101/2020.04.28.20083139. published online May 2. (preprint)
    1. Lavezzo E, Franchin E, Ciavarella C. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature. 2020;584:425–429.
    1. He X, Lau EHY, Wu P. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672–675.
    1. Kujawski SA, Wong KK, Collins JP. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26:861–868.
    1. Tan W, Lu Y, Zhang J. Viral kinetics and antibody responses in patients with COVID-19. medRxiv. 2020 doi: 10.1101/2020.03.24.20042382. published online March 26. (preprint)
    1. To KK-W, Tsang OT-Y, Leung W-S. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574.
    1. Wyllie AL, Fournier J, Casanovas-Massana A. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383:1283–1286.
    1. Young BE, Ong SWX, Kalimuddin S. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323:1488–1494.
    1. Huang J, Mao T, Li S. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. medRxiv. 2020 doi: 10.1101/2020.04.22.20071258. published online April 27. (preprint)
    1. Zhang N, Gong Y, Meng F, Bi Y, Yang P, Wang F. Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. medRxiv. 2020 doi: 10.1101/2020.03.28.20043059. published online March 30. (preprint)
    1. Zheng S, Fan J, Yu F. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ. 2020;369
    1. Cai Q, Huang D, Ou P. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75:1742–1752.
    1. Chen J, Qi T, Liu L. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80:e1–e6.
    1. Chen X, Zhu B, Hong W. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis. 2020;98:252–260.
    1. Chen Y, Chen L, Deng Q. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020;92:833–840.
    1. Fan L, Liu C, Li N. Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study. medRxiv. 2020 doi: 10.1101/2020.03.28.20045955. published online March 30. (preprint)
    1. Fang Z, Zhang Y, Hang C, Ai J, Li S, Zhang W. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. J Infect. 2020;81:147–178.
    1. Liu Y, Yan L-M, Wan L. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20:656–657.
    1. Shi J, Cheng C, Yu M. Systemic inflammatory cytokines associate with SARS-CoV-2 viral shedding time in Covid-19 inpatients. Res Sq. 2020 doi: 10.21203/-31556/v1. published online May 29. (preprint)
    1. Tan L, Kang X, Ji X. Validation of predictors of disease severity and outcomes in COVID-19 patients: a descriptive and retrospective study. Med. 2020 published online May 19.
    1. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
    1. Yongchen Z, Shen H, Wang X. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020;9:833–836.
    1. Hu X, Xing Y, Jia J. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ. 2020;728
    1. Xu K, Chen Y, Yuan J. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19) Clin Infect Dis. 2020;71:799–806.
    1. Yan D, Liu X-Y, Zhu YN. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 2020;56
    1. Wu Y, Guo C, Tang L. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;5:434–435.
    1. Tian D, Wang L, Wang X. Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19. Res Sq. 2020 doi: 10.21203/-29818/v1. published online June 1. (preprint)
    1. Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa451. published online April 17.
    1. Sakurai A, Sasaki T, Kato S. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020;383:885–886.
    1. Talmy T, Tsur A, Shabtay O. Duration of SARS-CoV-2 detection in Israel Defense Forces soldiers with mild COVID-19. J Med Virol. 2020 doi: 10.1002/jmv.26374. published online July 30.
    1. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa460. published online April 19.
    1. Shastri A, Wheat J, Agrawal S. Delayed clearance of SARS-CoV2 in male compared to female patients: high ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs. medRxiv. 2020 doi: 10.1101/2020.04.16.20060566. published online April 17. (preprint)
    1. Ling Y, Xu S-B, Lin Y-X. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020;133:1039–1043.
    1. Zha L, Li S, Pan L. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med J Aust. 2020;212:416–420.
    1. Liang M, Chen P, He M. Corticosteroid treatment in critically ill patients with COVID-19: a retrospective cohort study. Res Sq. 2020 doi: 10.21203/-27386/v1. published online May 11. (preprint)
    1. Hung IFN, Lung KC, Tso EYK. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704.
    1. Huang H, Guan L, Yang Y. Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study. Res Sq. 2020 doi: 10.21203/-24667/v1. published online April 24. (preprint)
    1. Zhou R, Li F, Chen F. Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis. 2020;96:288–290.
    1. Chau NVV, Thanh Lam V, Thanh Dung N. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa711. published online June 4.
    1. Arons MM, Hatfield KM, Reddy SC. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081–2090.
    1. Hu Z, Song C, Xu C. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63:706–711.
    1. Yang R, Gui X, Xiong Y. Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. JAMA Netw Open. 2020;3
    1. Bullard J, Dust K, Funk D. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa638. published online May 22.
    1. La Scola B, Le Bideau M, Andreani J. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059–1061.
    1. Le TQM, Takemura T, Moi ML. Severe acute respiratory syndrome coronavirus 2 shedding by travelers, Vietnam, 2020. Emerg Infect Dis. 2020;26:1624–1626.
    1. To KK-W, Tsang OT-Y, Yip CC-Y. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. 2020;71:841–843.
    1. Xiao F, Sun J, Xu Y. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis J. 2020;26:1920–1922.
    1. Andersson M, Arancibia-Carcamo CV, Auckland K. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. medRxiv. 2020 doi: 10.1101/2020.05.21.20105486. published online June 17. (preprint)
    1. Chang D, Mo G, Yuan X. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med. 2020;201:1150–1152.
    1. Chen X, Ling J, Mo P. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. medRxiv. 2020 doi: 10.1101/2020.03.03.20030437. published online March 6. (preprint).
    1. Corman VM, Rabenau HF, Adams O. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion. 2020;60:1119–1122.
    1. Fu S, Fu X, Song Y. Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China. medRxiv. 2020 doi: 10.1101/2020.04.03.20051763. published online April 6. (preprint).
    1. Huang L, Chen Z, Ni L. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on inflammatory responses and viral clearance in COVID-19 patients: a multicenter retrospective cohort study. Res Sq. 2020 doi: 10.21203/-27366/v1. published online May 8. (preprint)
    1. Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol. 2020;92:2286–2287.
    1. Liu L, Liu W, Zheng Y. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. Microbes Infect. 2020;22:206–211.
    1. Lo IL, Lio CF, Cheong HH. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16:1698–1707.
    1. Lou B, Li T-D, Zheng S-F. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020;56
    1. Pongpirul WA, Mott JA, Woodring JV. Clinical characteristics of patients hospitalized with coronavirus disease, Thailand. Emerg Infect Dis. 2020;26:1580–1585.
    1. Qian GQ, Chen XQ, Lv DF. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. Infect Dis. 2020;52:511–512.
    1. Quan W, Zheng Q, Tian J. No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China. medRxiv. 2020 doi: 10.1101/2020.03.26.20044198. published online March 30. (preprint)
    1. Seah IYJ, Anderson DE, Kang AEZ. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. Ophthalmology. 2020;127:977–979.
    1. Song C, Wang Y, Li W. Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients. medRxiv. 2020 doi: 10.1101/2020.03.31.20042333. published online April 10. (preprint).
    1. Song R, Han B, Song M. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. J Infect. 2020;81:e26–e30.
    1. Tu Y-H, Wei Y-Y, Zhang D-W, Chen C-S, Hu X-W, Fei G. Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study. Res Sq. 2020 doi: 10.21203/-20954/v1. published online April 6. (preprint)
    1. Wang L, Gao Y-h, Lou L-L, Zhang G-J. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J. 2020;55
    1. Wang S, Tu J, Sheng Y. Clinical characteristics and fecal-oral transmission potential of patients with COVID-19. medRxiv. 2020 doi: 10.1101/2020.05.02.20089094. published online May 6. (preprint)
    1. Wu B, Lei Z-Y, Wu K-L. Epidemiological and clinical features of imported and local patients with coronavirus disease 2019 (COVID-19) in Hainan, China. SSRN. 2020 doi: 10.2139/ssrn.3555222. published online March 24. (preprint)
    1. Xu l, Zhang X, Song W. Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China. medRxiv. 2020 doi: 10.1101/2020.02.23.20024935. published online Feb 25. (preprint)
    1. Yang Y, Yang M, Shen C. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020 doi: 10.1101/2020.02.11.20021493. published online Feb 17. (preprint)
    1. Zhu L, Gong N, Liu B. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;18:18.
    1. Chan PK, To WK, Ng KC. Laboratory diagnosis of SARS. Emerg Infect Dis. 2004;10:825–831.
    1. Chen WJ, Yang JY, Lin JH. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infect Dis. 2006;42:1561–1569.
    1. Liu W, Tang F, Fontanet A. Long-term SARS coronavirus excretion from patient cohort, China. Emerg Infect Dis. 2004;10:1841–1843.
    1. Xu D, Zhang Z, Jin L. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur J Clin Microbiol Infect Dis. 2005;24:165–171.
    1. Cheng PK, Wong DA, Tong LK. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004;363:1699–1700.
    1. Kwan BC, Leung CB, Szeto CC. Severe acute respiratory syndrome in dialysis patients. J Am Soc Nephrol. 2004;15:1883–1888.
    1. Leong HN, Chan KP, Khan AS. Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital. Emerg Infect Dis. 2004;10:1745–1750.
    1. Peiris JSM, Chu CM, Cheng VCC. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772.
    1. Min CK, Cheon S, Ha NY. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep. 2016;6
    1. Shalhoub S, Farahat F, Al-Jiffri A. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70:2129–2132.
    1. Al Hosani FI, Pringle K, Al Mulla M. Response to emergence of Middle East respiratory syndrome coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014. Emerg Infect Dis. 2016;22:1162–1168.
    1. Oh MD, Park WB, Choe PG. Viral load kinetics of MERS coronavirus infection. N Engl J Med. 2016;375:1303–1305.
    1. Arabi YM, Al-Omari A, Mandourah Y. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med. 2017;45:1683–1695.
    1. Hong KH, Choi JP, Hong SH. Predictors of mortality in Middle East respiratory syndrome (MERS) Thorax. 2018;73:286–289.
    1. Corman VM, Albarrak AM, Omrani AS. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016;62:477–483.
    1. Muth D, Corman VM, Meyer B. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol. 2015;53:2951–2955.
    1. Al-Jasser FS, Nouh RM, Youssef RM. Epidemiology and predictors of survival of MERS-CoV infections in Riyadh region, 2014–2015. J Infect Public Health. 2019;12:171–177.
    1. Alkendi F, Nair SC, Hashmey R. Descriptive epidemiology, clinical characteristics and outcomes for Middle East respiratory syndrome coronavirus (MERS-CoV) infected patients in AlAin – Abu Dhabi Emirate. J Infect Public Health. 2019;12:137.
    1. Park WB, Poon LLM, Choi SJ. Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection. Int J Infect Dis. 2018;72:8–10.
    1. Wang Y, Zhang D, Du G. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
    1. Wang Y, Tian H, Zhang L. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. BMJ Glob Health. 2020;5
    1. Cheng H-Y, Jian S-W, Liu D-P, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180:1156–1163.
    1. Memish A. Viral shedding and antibody response in MERS. Vox Sang. 2016;111(suppl 1):48–49.
    1. Wang W, Xu Y, Gao R. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844.
    1. Ip DKM, Lau LLH, Leung NHL. Viral shedding and transmission potential of asymptomatic and paucisymptomatic influenza virus infections in the community. Clin Infect Dis. 2017;64:736–742.
    1. Walsh KA, Jordan K, Clyne B. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357–371.
    1. Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health. 2020;5:e452–e459.

Source: PubMed

3
Abonnieren